Inceptionr LLC Acquires Shares of 10,732 TG Therapeutics, Inc. $TGTX

Inceptionr LLC acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,732 shares of the biopharmaceutical company’s stock, valued at approximately $357,000.

A number of other hedge funds have also recently modified their holdings of TGTX. Danske Bank A S purchased a new position in TG Therapeutics during the third quarter valued at approximately $25,000. Hantz Financial Services Inc. boosted its position in TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in TG Therapeutics by 86.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 573 shares in the last quarter. Truvestments Capital LLC grew its stake in shares of TG Therapeutics by 172.4% during the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,026 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $52,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Down 0.5%

TGTX opened at $55.75 on Tuesday. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $59.30. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28. The company has a 50-day moving average price of $49.34 and a 200 day moving average price of $38.26. The company has a market cap of $8.53 billion, a PE ratio of 19.49, a price-to-earnings-growth ratio of 1.40 and a beta of 1.60.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The firm had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same quarter in the previous year, the firm posted $0.03 earnings per share. The company’s quarterly revenue was up 69.5% on a year-over-year basis. Sell-side analysts expect that TG Therapeutics, Inc. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. B. Riley Financial boosted their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Bank of America lifted their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. HC Wainwright upped their price objective on shares of TG Therapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Jefferies Financial Group restated a “buy” rating and set a $83.00 target price on shares of TG Therapeutics in a research report on Monday, June 22nd. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, TG Therapeutics has an average rating of “Hold” and a consensus target price of $58.50.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.